Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
for AML With Gene Mutations
12 locations incl. Los Angeles
Sponsor: Lomond Therapeutics Holdings, Inc.
Sex: All·Age: 18+
Code: NCT06366789·Phase 1·Recruiting·Listed Apr 2024